Bio-Rad Introduces New And Improved
Liquichek™ Specialty Immunoassay Control 

HERCULES, CA – October 15, 2010
– Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the launch of the enhanced Liquichek™ Specialty Immunoassay Control.

Liquichek Specialty Immunoassay Control is a liquid third party control specially manufactured to monitor the precision of laboratory testing procedures for Intact PTH, Anti-Tg, Anti-TPO, C-Peptide, IGF-1, 25-Hydroxy Vitamin D and Osteocalcin. The enhancements include longer open vial stability for Anti-Tg & Anti-TPO and expanded testing methods for 25-OH Vitamin D. It is now offered in four individual levels to provide optimum values for the most popular test methods.

Liquichek Specialty Immunoassay Control is a human-based serum product supplied in a liquid form (frozen) that can be treated in the same manner as a patient specimen.

The Unity™ Interlaboratory Program is available for use with the Liquichek Specialty Immunoassay Control. Unity Real Time®, an expert QC data management software solution designed to improve the effectiveness of quality control processes, is also available.

With over 25 years experience as a leading provider of quality control products, Bio-Rad offers superior technical support and troubleshooting assistance.

For more information, please call 1-800-2-BIORAD (1-800-224-6723) or visit

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 6,800 people globally and had revenues of nearly $1.8 billion in 2009. For more information, visit

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact:
Lily Sunkin, Product Manager
Bio-Rad Laboratories, Inc.


Log In / Register

Log In / Register